Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies

Kidney International, Supplement

Volumn 62, Issue 82, 2002, Pages S47-S52

  Luño, José ^a   Barrio, Vicente ^a   Goicoechea, Maria Ángeles ^a   González, Cesar ^a   García de Vinuesa, Soledad ^a   Gómez, Francisco ^a   Bernis, Carmen ^a   Espinosa, Mario ^a   Ahijado, Francisco ^a   Gómez, José ^a   Escalada, Pedro ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Non diabetic nephropathies; Progressive renal disease; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; TETRAZOLE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPAIN; TIME; TREATMENT OUTCOME; URINE; ANTIHYPERTENSIVE THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONFIDENCE INTERVAL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY DISEASES; LISINOPRIL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SPAIN; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036433046     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.62.s82.10.x     Document Type: Article

References (32)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 11:1456-1462, 1993
2. Ravid M, Lang R, Rachmani R, Lischner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 156:286-289, 1996
3. Mogensen CE, Keane, WF, Bennett, PH, et al: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
4. Parving HH, Hovind P, Rossing K, et al: Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens 10:515-522, 2001
5. Maschio G, Alberti D, Janin A, et al, and the AIPRI Study Group: Effect of the angiotensin converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
6. Kshirsagar AV, Joy MS, Hogan SL, et al: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 35:695-707, 2000
7. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient level data. Ann Intern Med 135:73-78, 2001
8. Parving HH, Lehnert H, Bröchner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
9. Brenner BM, Cooper ME, De Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
10. Lewis ED, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
11. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN): Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk to terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
12. Remuzzi A, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
13. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue-evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387-392, 1998
14. Nussberger J, Brunner DB, Waeber B, Brunner HR: Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens 3(Suppl 3):S269-S270, 1985
15. Siragy HM: The role of the AT2 receptor in hypertension. Am J Hypertens 3 Suppl(5 Pt 2):62S-67S, 2000
16. Allen TJ, Cao Z, Youssef S, et al: The role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies. Diabetes 46:1612-1618, 1997
17. Russo D, Pisano A, Balletta MM, et al: Additive antiproteinuric effects of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
18. Ruilope LM, Aldigier JC, Ponticelli C, et al: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89-95, 2000
19. Ferrari P, Marti HP, Pfister M, Frey JF: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20:125-130, 2002
20. Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
21. Jacobsen P, Andersen S, Rossing K, et al: Dual blockade of the renin angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17:1019-1024, 2002
22. Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
23. The Sixth Report of the Joint National Committee on Prevention: Detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
24. Guidelines Subcommittee: World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 17:151-183, 1999
25. Mogensen CE: The reno-protective role of AT(1)-receptor blockers. J Hum Hypertens 16(Suppl 3):S52-S58, 2002
26. Hollenberg NK: Angiotensin converting enzyme inhibition and the kidney. Curr Opin Cardiol 3(Suppl 1):S19-S29, 1988
27. Remuzzi A, Mohamed EI: Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Exp Nephrol 4(Suppl 1):27-33, 1996
28. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 38(3 Pt 2):635-638, 2001
29. Komers R, Cooper ME: Acute renal hemodynamic effects of angiotensin converting enzyme inhibition in diabetic hyperfiltration: The role of kinins. Am J Physiol 268:F588-F594, 1995
30. Maillard MP, Wurzner G, Nussberger J, et al: Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther 71:68-76, 2002
31. Weinberg MS, Weimberg AJ, Cord R, Zappe DH: The effect of high dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS 2(Suppl 1):S196-S198, 2001
32. Bakris GL, Siomos M, Richardson D, et al: ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. VAL-K Study Group. Kidney Int 58:2084-2092, 2000